B. Nygaard et al., Serum levels of the cytokines IL-1 beta, IL-6 and ICAM-1 after I-131-treatment of Graves' disease and nodular goiter, HORMONE MET, 32(7), 2000, pp. 283-287
Cytokines might be involved in the immunological flare up, seen in some pat
ients after I-131-treatment. Therefore, we measured serum levels of interle
ukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-6 soluble recept
or (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor
necrosis factor (TNF-alpha) after I-131-treatment of Graves' disease and n
odular goiter. Seven patients with Craves' disease, eight with toxic nodula
r goiter and seven with non-toxic nodular goiter, were followed after I-131
-treatment. The patients were treated in the euthyroid state. Blood samples
were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases we
re seen in free T-4 index (FT4II), free T-3 index (FT3I) and thyroglobulin
(Tg) within the first weeks, and TSH simultaneously decreased. None of the
cytokines demonstrated any change during follow-up, neither in the entire g
roup nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In
conclusion, our data suggest that there does not seem to be prolonged cyto
kine activation after I-131-treatment for thyroid disorders.